Favipiravir

法匹拉韦

Report date: 2026/04/16 20:00:17
NMEFirst In Class

Base Information

Drug NameFavipiravir
Drug Alias Name法匹雷韦favipiravirum法维拉韦AviganReeqonus +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRNA-directed RNA polymerase inhibitors
TargetsRNA-directed RNA polymerase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Hepatic InsufficiencyCoronavirus Infections +[7] 
Global Approved IndicationsInfluenza, Human
Approved Indications in ChinaInfluenza, Human
Original Approved Country/TerritoryJapan
Original Approved Date2014/03/24
Country/TerritoryBelgiumBulgariaCanada +[37] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesToyama Chemical Co LtdTaisho Toyama
China Registration ClassN/A

Develop Information

Active CompaniesNational Institute Of Health Research And Development (Nihrd), IndonesiaInstitut National De La Santé Et De La Recherche Médicale, France U979Aaipharma +[9] 
Inactive CompaniesPromomed LLCGenuine Research Center, EgyptChromis Llc +[13] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Lassa FeverInfluenza, Human +[4] 
Inactive IndicationsHepatic InsufficiencyCoronavirus InfectionsHemorrhagic Fever, Ebola

Other Information

ATC CodeJ05AX27
Related LinksWikipediaDrugBankKEGG